ProCE Banner Series

Advances in Metastatic Breast Cancer: Antibody–Drug Conjugate Therapy for the Multidisciplinary Team

Register now for this live, 1-hour workshop to learn how medical oncologists, pharmacists, and nurses can effectively incorporate approved and emerging antibody–drug conjugates into the care of patients with metastatic breast cancer.

  ACPE
  | ACPE
  | AMA
  | ANCC
  | ANCC
Who Should Attend

This program is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients with metastatic breast cancer.

All Events

Past Events

March

25

2023

Advances in Metastatic Breast Cancer Care: Guidance on Antibody - Drug Conjugate Therapy for the Community Multidisciplinary Team

2:30 PM - 3:30 PM Pacific Time (PT)

In-person

Private Event, Las Vegas, Nevada

March

27

2023

Advances in Metastatic Breast Cancer Care: Guidance on Antibody - Drug Conjugate Therapy for the Community Multidisciplinary Team

7:00 PM - 8:00 PM Pacific Time (PT)

In-person

Private Event, Burlingame, California

April

19

2023

Advances in Metastatic Breast Cancer Care: Guidance on Antibody - Drug Conjugate Therapy for the Community Multidisciplinary Team

11:30 AM - 12:30 PM Central Time (CT)

Virtual

Private Event, Decatur, Texas

April

22

2023

Advances in Metastatic Breast Cancer Care: Guidance on Antibody - Drug Conjugate Therapy for the Community Multidisciplinary Team

8:30 AM - 9:30 AM Central Time (CT)

In-person

Private Event | Host Group Houston, Houston, Texas

May

10

2023

Advances in Metastatic Breast Cancer Care: Guidance on Antibody - Drug Conjugate Therapy for the Community Multidisciplinary Team

8:30 AM - 9:30 AM Eastern Time (ET)

Virtual

Private Event, Hendersonville, North Carolina

May

15

2023

Advances in Metastatic Breast Cancer Care: Guidance on Antibody - Drug Conjugate Therapy for the Community Multidisciplinary Team

10:30 AM - 11:30 AM Mountain Time (MT)

Virtual

Private Event, Rio Rancho, New Mexico

May

16

2023

Advances in Metastatic Breast Cancer Care: Guidance on Antibody - Drug Conjugate Therapy for the Community Multidisciplinary Team

12:00 PM - 1:00 PM Central Time (CT)

Virtual

Private Event | Host Group Columbia, Columbia, Missouri

May

18

2023

Advances in Metastatic Breast Cancer Care: Guidance on Antibody - Drug Conjugate Therapy for the Community Multidisciplinary Team

6:00 PM - 7:00 PM Pacific Time (PT)

In-personVirtual

Private Event | Host Group at Beverly's, Post Falls, Idaho

May

19

2023

Advances in Metastatic Breast Cancer Care: Guidance on Antibody - Drug Conjugate Therapy for the Community Multidisciplinary Team

3:30 PM - 4:30 PM Eastern Time (ET)

Virtual

Private Event | Host Group Lexington, KY, Lexington, Kentucky

May

26

2023

Advances in Metastatic Breast Cancer Care: Guidance on Antibody - Drug Conjugate Therapy for the Community Multidisciplinary Team

12:00 PM - 1:00 PM Eastern Time (ET)

In-person

Private Event | Host Group Brooklyn, Brooklyn, New York

May

26

2023

Advances in Metastatic Breast Cancer Care: Guidance on Antibody - Drug Conjugate Therapy for the Community Multidisciplinary Team

7:00 PM - 8:00 PM Eastern Time (ET)

In-person

Private Event | Host Group at Nanking, New Hyde Park, New York

June

06

2023

Advances in Metastatic Breast Cancer Care: Guidance on Antibody - Drug Conjugate Therapy for the Community Multidisciplinary Team

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group MI, Royal Oak, Michigan

June

20

2023

Advances in Metastatic Breast Cancer Care: Guidance on Antibody - Drug Conjugate Therapy for the Community Multidisciplinary Team

5:00 PM - 6:00 PM Eastern Time (ET)

Virtual

Private Event | Virtual Group, Newport News, Virginia

June

22

2023

Advances in Metastatic Breast Cancer Care: Guidance on Antibody - Drug Conjugate Therapy for the Community Multidisciplinary Team

8:00 AM - 9:00 AM Eastern Time (ET)

Virtual

Private Event | Virtual Group, Elizabeth, New Jersey

June

27

2023

Advances in Metastatic Breast Cancer Care: Guidance on Antibody - Drug Conjugate Therapy for the Community Multidisciplinary Team

8:00 AM - 9:00 AM Central Time (CT)

Virtual

Private Event | Virtual Group, Chicago, Illinois

June

30

2023

Advances in Metastatic Breast Cancer Care: Guidance on Antibody - Drug Conjugate Therapy for the Community Multidisciplinary Team

8:00 AM - 9:00 AM Central Time (CT)

Virtual

Private Event | Virtual Group, Tulsa, Oklahoma

July

12

2023

Advances in Metastatic Breast Cancer Care: Guidance on Antibody - Drug Conjugate Therapy for the Community Multidisciplinary Team

4:30 PM - 5:30 PM Central Time (CT)

Virtual

Webinar | Host Group OK, Norman, Oklahoma

July

19

2023

Advances in Metastatic Breast Cancer Care: Guidance on Antibody - Drug Conjugate Therapy for the Community Multidisciplinary Team [Open Registration]

12:00 PM - 1:00 PM Central Time (CT)

Virtual

CCO Simulcast | Host Group AL, Mobile, Alabama

July

20

2023

Advances in Metastatic Breast Cancer Care: Guidance on Antibody - Drug Conjugate Therapy for the Community Multidisciplinary Team

5:30 PM - 6:30 PM Eastern Time (ET)

Virtual

Private Event | Host Group Tampa, Tampa, Florida

July

24

2023

Advances in Metastatic Breast Cancer Care: Guidance on Antibody - Drug Conjugate Therapy for the Community Multidisciplinary Team

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Private Event | Host Group Charlotte, Charlotte, North Carolina

Faculty

ProCE Banner Faculty
Ana Garrido-Castro, MD

Assistant Professor 
Department of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Insitute
Boston, Massachusetts

 

ProCE Banner Faculty
Komal Jhaveri, MD, FACP

Patricia and James Cayne Chair for Junior Faculty
Associate Attending Physician
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

ProCE Banner Faculty
Rashmi Murthy, MD, MBE

Associate Professor
Department of Breast Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

ProCE Banner Faculty
Rita Nanda, MD

Associate Professor of Medicine
Director, Breast Oncology
Section of Hematology/Oncology
Department of Medicine
The University of Chicago
Chicago, Illinois

ProCE Banner Faculty
Hatem Soliman, MD

Hatem Soliman, MD 
Associate Professor
Division of Oncology Sciences
University of South Florida
Associate Member, Breast Medical Oncologist 
Breast, Tumor, Biology, and Immunology Departments
H. Lee Moffitt Cancer Center and Research Institute 
Tampa, Florida 

ProCE Banner Faculty
Sara M. Tolaney, MD, MPH

Assistant Professor of Medicine
Harvard Medical School
Associate Director
Susan F. Smith Center for Women’s Cancers
Director
Clinical Trials, Breast Oncology
Director
Breast Immunotherapy Clinical Research
Dana-Farber Cancer Institute
Boston, Massachusetts

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners to integrate currently available and emerging data on antibody–drug conjugate therapies into clinical practice for patients with metastatic breast cancer.

Target Audience
This program is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients with metastatic breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Compare the available antibody–drug conjugate therapies used in the treatment of metastatic breast cancer, considering antibody target, mechanism of action, overall construct, efficacy, and safety profile
  • Plan individualized treatment strategies for patients with HER2-low metastatic breast cancer, considering recent clinical data and expert recommendations
  • Select optimal second-line antibody–drug conjugate therapy for patients with HER2-positive metastatic breast cancer based on available clinical data and expert recommendations
  • Develop clinical strategies for the early identification and management of treatment-related symptoms associated with antibody–drug conjugates
  • Identify emerging targets for precision therapy with antibody–drug conjugates that may provide future treatment options for the treatment of metastatic breast cancer

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-015-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.